Page 10«..9101112..2030..»

Category Archives: Genetic Engineering

Eligo unlocks next generation of precision genetic medicine with foundational patents granted covering in-situ base editing of the microbiome and…

Posted: July 3, 2022 at 2:12 am

Base editing technology has already shown significant potential for genome engineering of human cells to treat serious and life-threatening hereditary diseases. Recent scientific advances have identified causative roles for genes from commensal microbiota in the pathogenesis or aggravation of an increasing number of diseases, such as lupus, rheumatoid arthritis and myocarditis. In-situ precision engineering of the microbiome with gene editing technologies, including base editing technology, represents a promising frontier of medical innovation and opens new and highly valuable therapeutic opportunities.

The two broad and foundational patents granted to Eligo, US11,224,621 and US11,376,286, cover the unique ability to modify with unprecedented precision the genome of deeply-engrafted resident bacteria without killing them. In particular, it enables targeted and durable modification or inactivation of bacterial proteins from essential commensal bacteria. This approach can uniquely address key unmet needs in microbiome-related diseases, by removing bacterial triggers of disease while maintaining commensal bacteria that are essential to our health.

Eligo revealed, during a presentation at CRISPR 2022 conference in Boston, that a single oral dose of a base-editor equipped medicine led to the precise editing of up to 100% of a target bacterial population in the gut of animals in a matter of hours. They also demonstrated that such edits were stable over time.

"The grant of these broad patents is an important milestone for Eligo Bioscience as it significantly broadens the potential for our proprietary gene editing platform in microbiome-related diseases, in addition to the use of CRISPR to kill specific bacterial populations." said Dr. Xavier Duportet, Chief Executive Officer of Eligo Bioscience. "It consolidates our position as pioneer and leader in the field of in situ prokaryotic editing. Eligo Bioscience has indeed the earliest position both in fields of CRISPR killing and now base editing also."

About the patents

Patents US11,224,621 and US11,376,286 are members of a patent family published as WO2021/204967, entitled "Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders'' and cover method of use and composition of matter claims respectively. Eligo is prosecuting multiple patent applications outside of the US as well.

About Eligo

Eligo Bioscience is the world leader in microbiome gene editing therapy and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in inflammation, autoimmunity and oncology caused by the expression of specific deleterious bacterial genes by our microbiome.

Eligo was founded by scientists from The Rockefeller University, where CRISPR-based antimicrobials were invented, and by scientists from MIT. Eligo was named a Technology Pioneer by the World Economic Forum in 2017. Eligo has received venture capital funding from Khosla Ventures and Seventure Partners, and non-dilutive funding from GlaxoSmithKline, the European Commission, CARB-X, and Bpifrance.

Photo - https://mma.prnewswire.com/media/1849676/Eligo_Bioscience_Image.jpgLogo - https://mma.prnewswire.com/media/1533529/Eligo_Bioscience_SA_Logo.jpg

Contact:DUPORTET Xavier [emailprotected]

SOURCE Eligo Bioscience

Read more here:
Eligo unlocks next generation of precision genetic medicine with foundational patents granted covering in-situ base editing of the microbiome and...

Posted in Genetic Engineering | Comments Off on Eligo unlocks next generation of precision genetic medicine with foundational patents granted covering in-situ base editing of the microbiome and…

Gene Changes Previously Thought as Neutral Are Now Shown to Be Deleterious in Yeast – Gilmore Health News

Posted: July 3, 2022 at 2:12 am

The early 1960s saw the crack of the genetic code. This scientific breakthrough brought advancement in biological and cellular studies. The underlying feature of the genetic code explains how DNA converts into protein. Codons are three-letter units found in DNA orders. Within these codons are the 20 amino acids that make up proteins in the human body. Mutations occur in gene codes as a letter or point change.

Genes

Read Also: Congenital Mirror Movement Disorder Caused by a Mutation in the RAD51 Gene French Study Shows

There are two common types of these mutations. Silent mutations are changes in different parts of the DNA that dont affect the protein order produced. Non-silent (non-synonymous) mutations cause changes in the protein order.

Previously held scientific beliefs have been that these silent mutations are neutral. However, a new study has demonstrated these silent changes are dangerous. This study is available in the journal Nature.

Various studies have attempted to clarify the role of mutations in gene expression and diseases. The DNA sequence in proteins contains point changes that are silent in several cases. The sequencing of protein is unaffected by the changes. The point mutations are changes that do not affect protein sequence and are thought to be neutral since the 1960s. Researchers conducted experimental studies on the mechanisms of yeast gene engineering. The study result shows a high negative impact of silent gene changes (75.9%).

The results of this current study have a wide-ranging effect. In checking diseased mutations, scientists can recognize the role of both silent and non-silent mutations. The research in this innovative investigation also aimed to identify exceptions to the non-neutrality of silent mutations. Although some scientists believe that silent mutations are not neutral, there has not been much literature on the non-neutral exceptions.

The study subject was yeast. Since yeast has a short growth time and is tiny, the scientists checked the impact of these silent mutations on the organism fairly rapidly, accurately, and easily.

Read Also: Genomic Inversions Are More Common in Genetic Diseases Study Shows

The study scientists used CRISPR/Cas9 genome editing to determine more than 8000 mutant yeast sequences. Each of the sequences contained either a silent, non-silent, or nonsense mutation. Although 1.3% of the silent mutations discovered were highly advantageous, 75.9% were detrimental.

Additionally, the study investigated other mechanisms by which these silent changes affected Darwinian fitness. They discovered that both silent and non-silent mutations affect the gene expression level and the magnitude of these expressional changes shows the fitness effect.

This study is significant in disease study and evolution biology. Because these silent mutations are harmful in yeast, clinicians and researchers can re-examine their previously held belief of its non-deleterious effects. This is significant because these silent mutations are now equally important in the pathogenesis of diseases.

The current study shows severe negative impacts of these silent mutations in yeast. Decades of consensus on the neutrality of silent gene changes may now be proven false. Understanding the mechanism of these changes can be beneficial for gene expression studies.

Read Also: Scientists Identify Gene Complex That Regulates Ribosome Production

Synonymous mutations in representative yeast genes are mostly strongly non-neutral

Continue reading here:
Gene Changes Previously Thought as Neutral Are Now Shown to Be Deleterious in Yeast - Gilmore Health News

Posted in Genetic Engineering | Comments Off on Gene Changes Previously Thought as Neutral Are Now Shown to Be Deleterious in Yeast – Gilmore Health News

Directors Kristina Buoyt and Bruno Samper on their 10-year odyssey to make bio-punk fairy tale ‘Vesper’ – Screen International

Posted: July 3, 2022 at 2:12 am

Lithuanias Kristina Buoyt and Frances Bruno Sampers Vesper is world premiering this weeked in the Crystal Globe Competition at the Karlovy Vary International FIlm Festival.

The film is a dystopian sci-fi in which 13-year-old Vesper, played by Raffiella Chapman, tries to eke out an existence on an ecologically ravaged Earth. Caring for her paralysed father, Vesper comes across a mysterious girl (Rosie McEwen) who originates from the Citadel the place where the rich and powerful dwell. UK actor Eddie Marsan co-stars.

Vesper marks a return to the festival for Buoyt and Samper after their 2012 film Vanishing Waves, directed by Buoyt and co-written by Samper, debuted in the festivals now defunct East of the West competition garnering a special mention. It went on to be a sizable hit on the festival circuit and beyond.

Vesper is produced by Lithunian production company Natrix Natrix and France- based Rumble Fish Productions. Co-producers are Belgiums 10.80 Films and French company EV.L Prod. International sales are handled by UK based Anton. The films has already been sold to a number of territories including North America (IFC Films) and UK (Signature Entertainment)

Aside from a segment in 2014s ABCs of Death 2, its been 10 years since your previous film, Vanishing Waves. Was it difficult to bring Vesper to the big screen?

Kristina Buoyt: During these 10 years, we were actually pretty busy. We have been developing different English- language film projects that we wanted to shoot abroad. The majority got lost in so-called development limbo. Then we decided to return to our roots - to write a script that would be ambitious but possible to shoot in Lithuania. That is how Vesper came about.

Bruno Samper: Looking back now, we realise that we integrated the lesson learned from these 10 years into the plot for Vesper dont search for a utopic promised land elsewhere, but instead use your roots and your ambition to change the reality of where you are.

What inspired the story of the film?

KB: Our desire was to make a movie about hope. Even in the worst and most desperate situations, if we are able to see beauty, it wont be easy but we will always have a reason to live, to fight, and to change the order of things. We would like the film to touch especially the young generation who constantly hear that our world is dying and theres no future. Young people dont merely want to survive, they want to live. The pandemic very forcefully brought that point home.

BS: Also, we wanted to create a world never seen on the big screen and the biopunk fairy-tale genre gave us this possibility. We worked on this universe for several years. We did a lot of research about the most recent innovations in organic architecture, bio-design, genetic engineering, and even the sexuality of plants.

How did you find Raffiella Chapman andgo about finding her and preparing her for the role?

KB: Raffi is real gem - talented, a fast-learner and hard-worker, and she totally embodies her generation. She is all a director could wish for. When Bruno saw her casting video, he saw Vesper.

BS: She was totally invested in the project.The shooting could be very demanding at times, and she always gave more than her best. Her parents were also very supportive which was a huge help.

What influenced you when making the film?

KB: Beyond the science-fiction framework, Vesper is an initiation story with a message for a society that is turning more and more towards escapism. Faced with problems - economic, social, political - more and more people prefer to flee into the denial of reality rather than face and solve the issues.

Also, for us it was very important to create a character who refuses to be a victim and manages to stand up and go forward despite all difficulties.

Is there a certain amount of difficulty for filmmakers in small regions such as the Baltics to make genre films?

KB: Its a question of time, the young generation doesnt make this separation anymore between genre and non-genre. Of course, the budget is always a challenge. There is certainly the energy, the desire and the ambition but we need to bring more private investment for Baltics projects. We hope Vesper will show that making a film like Vesper is possible even within the current economic structures of the film industry.

Read the original post:
Directors Kristina Buoyt and Bruno Samper on their 10-year odyssey to make bio-punk fairy tale 'Vesper' - Screen International

Posted in Genetic Engineering | Comments Off on Directors Kristina Buoyt and Bruno Samper on their 10-year odyssey to make bio-punk fairy tale ‘Vesper’ – Screen International

SMART research reveals promising uses of non-destructive sensors to aid food security and enhance sustainable agriculture – EurekAlert

Posted: July 3, 2022 at 2:12 am

SMART research reveals promising uses of non-destructive sensors to aid food security and enhance sustainable agriculture

Recent advancements of in vivo and surface or airborne sensors to diagnose plant health will improve crop growth and minimise resources used

Singapore, 30 June 2022 Researchers from the Disruptive & Sustainable Technologies for Agricultural Precision (DiSTAP) Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, and their local collaborators from the Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR) as well as the Department of Chemical and Biomolecular Engineering (ChBE), National University of Singapore (NUS) have published a review that discusses the recent advances in non-destructive plant health monitoring, ranging from electrochemical-based arrays to nanosensors and electronic noses, and why tracking plant health is an attractive and sustainable strategy that can be used to optimise crop growth practices. The review aims to inspire future developments of non-destructive technologies for plant health diagnosis.

To meet the pressing need for global food security and pave the way for sustainable agriculture, the advancement and adoption of agricultural technology are critical in alleviating the conditions of 193 million people in the world who are acutely food insecure. However, sustainable practices need to be implemented to minimise environmental destruction when improving crop yields and productivity. Traditionally, farmers will often only be able to notice signs of their crops' health deteriorating at a stage where reparative measures are limited.

Additionally, the current testing via chromatography-based analytical techniques is destructive as it requires, punching out leaf samples that would cause wounding and tissue breakdown. These methods are also laborious, including lab-based extraction and processing of multiple plant samples for every data point. Thus, scientists have been advancing the field of precision agriculture, developing novel sensors and analytical tools to help farmers guide farm-management decisions. The use of non-destructive or minimally invasive sensors for plant metabolites has emerged as an essential analytical tool for real-time monitoring of plant signalling pathways and plant response to external conditions that indicate overall plant health. These sensors could be incorporated into future farming practices and implemented in high-tech urban farms that use precision, predictive and environmentally controllable farming.

In light of the increasing demand for food due to the growing global population and concern over food security, developing innovative and sustainable technologies and tools to improve crop yield and quality is timely and essential. Non-destructive plant health monitoring stands as one of the key strategies for improving crop growth practices, complementing current agricultural techniques such as crop rotation, intercropping and genetic modification, said Dr Gajendra Pratap Singh, Principal Investigator and Senior Scientific Director at DiSTAP.

The team explained their research in the review article titled Non-destructive Technologies for Plant Health Diagnosis, published in the prestigious journal Frontiers in Plant Science. The findings showed that the sensors could be broadly categorised into those that detect internal (in vivo sensors) and external (plant surface and airborne) signalling molecules.

In vivo sensors are based on either electrochemical sensors or plant nano-bionic sensors. Recent nanotechnology advances have enabled electrochemical and plant nano-bionic sensors to exhibit higher sensitivity and selectivity by utilising unique electrochemical and optical properties. Besides internal signalling molecules, plants also emit signals at the surfaces of their organs as well as through airborne metabolites such as volatile organic compounds (VOCs) for inter-plant communication. Detection of internal and external cues, such as surface and airborne compounds, allows for the non-invasive and real-time diagnosis of plant diseases.

Furthermore, the sensors convert plant signals into digital signals to establish direct communication between plants and growers. By tapping into plants physiological events in real-time, non-destructive sensors enable prompt adjustment of environmental conditions to augment crop productivity while minimising resource use, added Dr Tedrick Thomas Salim Lew, Scientist at A*STARs IMRE and Adjunct Assistant Professor at NUS ChBE, who was the corresponding author of the article.

The review gave insights into sensors which are versatile and have been successful in extracting spatiotemporal information from a variety of agriculturally important plant species. The sensors will open the possibility of real-time feedback control schemes that can aid in the precise application of fertilisers and plant growth regulators to maximise growth, as well as facilitate timely intervention to minimise yield loss from plant stress, said Mervin Ang, Research Scientist at DiSTAP and first author of the article.

To address profound challenges in food production in Singapore and the world, DiSTAP has, over the years, introduced novel analytical tools that are rapid, non-destructive and have the ability to detect and provide information from living plants in real-time. This latest review seeks to advance technologies which can be applied to study agriculturally relevant crops in the field, bridging the knowledge gap between model plants commonly used in plant biology and economically important crops.

The review was supported by the National Research Foundation of Singapore under its Campus for Research Excellence And Technological Enterprise (CREATE) programme and the Agency for Science, Technology and Research (A*STAR) Career Development Fund.

###

Frontiers in Plant Science

Literature review

Not applicable

Non-destructive Technologies for Plant Health Diagnosis

30-Jun-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the rest here:
SMART research reveals promising uses of non-destructive sensors to aid food security and enhance sustainable agriculture - EurekAlert

Posted in Genetic Engineering | Comments Off on SMART research reveals promising uses of non-destructive sensors to aid food security and enhance sustainable agriculture – EurekAlert

Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium – GuruFocus.com

Posted: July 3, 2022 at 2:12 am

PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics ( IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will participate in a fireside chat at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:30 AM ET.

A live webcast of the fireside chat will be available on the Events & Presentations page in the Investors section of the Companys website at https://investors.centurytx.com/events-and-presentations. A replay of the webcast will be archived on the Companys website for 30 days following the presentation.

About Century Therapeutics

Century Therapeutics ( IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit http://www.centurytx.com.

Century Therapeutics Forward-Looking Statement

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as may, might, will, should, expect, plan, aim, seek, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, forecast, potential or continue or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the Risk Factors section of our most recent filings with the Securities and Exchange Commission and available at http://www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information: Company: Elizabeth Krutoholow [emailprotected]Investors: Melissa Forst/Maghan Meyers [emailprotected]Media: Joshua R. Mansbach [emailprotected]

Visit link:
Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium - GuruFocus.com

Posted in Genetic Engineering | Comments Off on Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium – GuruFocus.com

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board – Business Wire

Posted: July 3, 2022 at 2:12 am

MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.

We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics, said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. Joys expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases.

Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administrations (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Societys 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.

Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome, said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need.

About Life Edit Therapeutics Inc.

Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the worlds largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.

See more here:
Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board - Business Wire

Posted in Genetic Engineering | Comments Off on Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board – Business Wire

CRISPR Therapeutics to Host Innovation Day on June 21, 2022 – GuruFocus.com

Posted: June 22, 2022 at 2:46 am

ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics ( CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET.

CRISPR Therapeutics Innovation Day will focus on the Company's differentiated genetic engineering platform technologies, novel approach to cell and gene therapy, and emerging discovery programs.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 30 days following the presentation. Please contact [emailprotected] for any questions regarding the event.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503[emailprotected]

Media Contact:Rachel Eides+1-617-315-4493[emailprotected]

See the rest here:
CRISPR Therapeutics to Host Innovation Day on June 21, 2022 - GuruFocus.com

Posted in Genetic Engineering | Comments Off on CRISPR Therapeutics to Host Innovation Day on June 21, 2022 – GuruFocus.com

Gene edited foods back on the menu – what are they and what’s changed? – ABC News

Posted: June 22, 2022 at 2:46 am

Scientists Jonathan Napier and Cathie Martin remember when they needed armed guards and high fences to protect their research sites.

Genetically modified (GM) food crops were the target of activists concerned about genetic engineering.

But the strict laws governing their crops are now rapidly changing.

So are the definitions of what gets called a GM food and what doesn't.

What could this mean for your dinner plate? And have scientists learnt anything from the heated debates around GM about better involving citizens in decisions around their research?

GUESTS

Simon BurallSenior associate, InvolveMember, Nuffield Council on Bioethics

Professor Michael JonesProfessor of agricultural biotechnologyFoundation of the WA State Agricultural Biotechnology Centre

Professor Cathie MartinPlant scientistJohn Innes Centre, UK

Professor Jonathan NapierPlant scientist and metabolic engineerRothamsted Research, UK@johnathannapie1

FURTHER INFORMATION

Biofortified tomatoes provide a new route to vitamin D sufficiency (Nature, 2022)

CRISPR editing of plants and animals gets green light in Australia. Now what? (2019)

Genetic Technology (Precision Breeding) Bill (UK)

Nuffield Council commentary on the UK's Genetic Technology (Precision Breeding) Bill

Australia's gene technology regulatory system

CRISPR co-inventor Jennifer Doudna, and debating the ethics of gene editing (Science Friction, 2018)

Making happier animals? Gene editing in the farm-yard (Science Friction, 2017)

View post:
Gene edited foods back on the menu - what are they and what's changed? - ABC News

Posted in Genetic Engineering | Comments Off on Gene edited foods back on the menu – what are they and what’s changed? – ABC News

Alumni Entrepreneurs Pitch Startups to Impact the World – Princeton Alumni Weekly

Posted: June 22, 2022 at 2:46 am

Participants at the 2022 Tiger Entrepreneurs Conference and Pitch Competition: (from left) Tom Meyer 87, Cornelia Huellstrunk, Mayra Ceja 03, Joyce Zhang Gray *15, Eli Kalfaian 22, Julia Macalaster 12, Bayo Okusanya 20.

Wright Seneres

Participants at the 2022 conference had ideas for curbing noise pollution, harnessing fusion for zero-emission energy, and more

Before the blast of fireworks displays and Abba cover bands at Reunions, a group of alumni shared their startup dreams at the 2022 Tiger Entrepreneurs Conference and Pitch Competition.

Organized by the Princeton Entrepreneurship Counciland thePrinceton Entrepreneurs Network, the conference consisted of panel discussions, fireside chats, and networking opportunities, all of which culminated in a pitch competition adjudicated by conference attendees and a panel of investors.

Anne-Marie Maman 84, executive director of the Princeton Entrepreneurship Council, set the tone for the day during the opening panel.

We dont care if youre from the arts or the sciences, if youre for-profit or nonprofit, if youre business-to-business or business-to-consumer, Maman said, referring to the councils mission. What we care about is impact, the potential for your idea to make change.

The showcase floor displayed a strong sense of this impact-driven motivation, with startups that includedGetNoisy, which seeks seeking to curb noise pollution caused by aircraft traffic;Nucleos, an online learning platform designed to educate those in the carceral system; andPrinceton Stellarators Inc., which aims to use seeks to use fusion to create sustainable, zero-emission energy.

While individual startups were diverse in focus, each entrepreneur had strong, often personal motivation for getting their idea off the ground.

ConsiderConcarlo Therapeutics, which seeks to provide transformative therapies for drug-resistant cancers. The founder, Stacy Blain 89, said she decided to name the company by combining the names of her three kids, Connor, Carly, and Logan.

I do what I do because I want to make the world a better place for the next generation, Blain explained. Being reminded that Im doing this for the world that [my kids] are going to live in, thats what keeps me going.

Many of the founders were far removed from the business world while studying at Princeton. A majority of their paths to entrepreneurship are rooted in other interests microbiology, politics, computer tech, food science. Instead of being drawn to entrepreneurship for its own sake, these founders motivations are anchored by the conviction that they have something that the world needs, something that can drive positive change.

When we were first starting up, we called up 10 friends who we thought would be interested, Lauren Imparato 02, founder of health and wellness companyI.AM.YOU., recalled. The first thing they said was, What? Werent you SPIA [School of Public and International Affairs]?

Of the 16 varied startups on the showcase floor, three reached the final round:Alariss Global, an international business development service;Piggyback Network Inc., a carpooling app for families; andExpressCells, a genetic engineering company.

After a final pitch round and Q&A, ExpressCells was chosen as the competitions winner. ExpressCells promises to provide genetically edited cell lines months faster, which can help speed up scientific research and discovery. Matthew Handel 87, the companys CEO, accepted the $5,000 prize and will be given the opportunity to pitch ExpressCells to a variety of investors.

Read the original post:
Alumni Entrepreneurs Pitch Startups to Impact the World - Princeton Alumni Weekly

Posted in Genetic Engineering | Comments Off on Alumni Entrepreneurs Pitch Startups to Impact the World – Princeton Alumni Weekly

Global Therapeutic Proteins Market Research Report 2022: Focus on Insulin; Fusion Protein; Erythropoietin; Interferon; Human Growth Hormone; Follicle…

Posted: June 22, 2022 at 2:46 am

DUBLIN--(BUSINESS WIRE)--The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering.

The global therapeutic proteins market is expected to grow from $100.06 billion in 2021 to $112.17 billion in 2022 at a compound annual growth rate (CAGR) of 12.1%. The market is expected to reach $177.30 billion in 2026 at a CAGR of 12.1%.

The therapeutic proteins market consists of sales of therapeutic proteins. Therapeutic proteins provide important therapies for diseases such as diabetes, cancer, infectious diseases, hemophilia, and anemia.

The main types of products in therapeutic proteins are insulin, fusion protein, erythropoietin, interferon, human growth hormone and follicle stimulating hormone. Insulin is a peptide hormone produced by beta cells in the pancreatic cells that serves as the individual 's primary anabolic hormone. It affects fat, carbohydrate and protein metabolism by boosting glucose uptake from the blood into the fat, liver and skeletal muscle cells.

The different functions include enzymatic and regulatory activity, special targeting activity, vaccines, protein diagnostics and is used in various applications such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, others.

Advance technologies for protein-based drug development drives the therapeutic proteins market. Therapeutic proteins cannot be synthesized chemically, they need to be produced by genetic engineering and recombinant DNA technology in living cells or organisms.

Protein-engineering platform technologies such as glycoengineering, pegylation, Fc-fusion, albumin fusion, albumin drug conjugation help to increase the production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, coagulation factor IX recombinant human are some therapeutic protein drugs developed using protein engineering technologies approved by FDA in the past five years.

Increasing biosimilar drugs in global market decline the growth of the therapeutic proteins market. Patent expiry of therapeutic proteins such as monoclonal antibodies give space for entry of biosimilar. In EU, AbbVie evidenced patent expiration of Humira (adalimumab) in 2018, five biosimilar of Humira from Mylan, Amgen, Sandoz, Samsung Bioepis received drug approvals from European commission to enter the EU market. These cost-effective treatments similar to original biologics decline the revenue and sales of therapeutic proteins.

Monoclonal antibody drug approvals are increasing in the protein therapeutic segment. Chronic diseases such as cancer, immunological disorders are well treated with monoclonal antibodies. Monoclonal antibodies are dominant and well-established product class in the protein therapeutic segment with more safety and immunogenicity than antibodies.

Cell-based expression systems such as Chinese hamster ovary (CHO) mammalian cell expression system with latest technologies increased the productivity of monoclonal antibodies by overcoming the problems associated with earlier antibody drugs. In last five years, FDA approved 213 drugs, among them 44 are monoclonal antibodies. For instance, twelve monoclonal antibodies were approved by FDA for the treatment of cancer and immunological disorders.

In the United States, therapeutic protein drug manufacturers file therapeutic biologics application (BLA) to FDA for the product approvals. The drug approved through BLA should be proved as safe, pure and potent. FDA consolidated review of most therapeutic proteins in Center for Drug Evaluation and Research (CDER). In European Union, biologics are regulated by Committee for Medicinal Products for Human Use (CHMP) for marketing authorization.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company acquired Protomer Technologies Inc. for $1 billion. Lilly is delighted to add protomer's breakthrough technology to its diabetes pipeline through this acquisition, since the company's glucose-sensing insulin programme, which is based on its proprietary molecular engineering of protein sensors (MEPS) platform, is exhibiting great potential.

Major players in the therapeutic proteins market are

Key Topics Covered:

1. Executive Summary

2. Therapeutic Proteins Market Characteristics

3. Therapeutic Proteins Market Trends And Strategies

4. Impact Of COVID-19 On Therapeutic Proteins

5. Therapeutic Proteins Market Size And Growth

5.1. Global Therapeutic Proteins Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Therapeutic Proteins Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Therapeutic Proteins Market Segmentation

6.1. Global Therapeutic Proteins Market, Segmentation By Product Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.2. Global Therapeutic Proteins Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

6.3. Global Therapeutic Proteins Market, Segmentation By Function, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7. Therapeutic Proteins Market Regional And Country Analysis

7.1. Global Therapeutic Proteins Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Therapeutic Proteins Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/ktb394

View original post here:
Global Therapeutic Proteins Market Research Report 2022: Focus on Insulin; Fusion Protein; Erythropoietin; Interferon; Human Growth Hormone; Follicle...

Posted in Genetic Engineering | Comments Off on Global Therapeutic Proteins Market Research Report 2022: Focus on Insulin; Fusion Protein; Erythropoietin; Interferon; Human Growth Hormone; Follicle…

Page 10«..9101112..2030..»